Safety of recombinant human deoxyribonuclease as a rescue treatment for persistent atelectasis in newborns

Atiye Fedakar; Cavit Aydogdu; Ali Fedakar; Murat Ugurlucan; Semih Bolu; İskender, Murat

dc.contributor.authors	Fedakar, A; Aydogdu, C; Fedakar, A; Ugurlucan, M; Bolu, S; Iskender, M;
dc.date.accessioned	2020-02-24T13:38:08Z
dc.date.available	2020-02-24T13:38:08Z
dc.date.issued	2012
dc.identifier.citation	Fedakar, A; Aydogdu, C; Fedakar, A; Ugurlucan, M; Bolu, S; Iskender, M; (2012). Safety of recombinant human deoxyribonuclease as a rescue treatment for persistent atelectasis in newborns. , 32, 136-131
dc.identifier.issn	0256-4947
dc.identifier.uri	https://doi.org/10.5144/0256-4947.2012.131
dc.identifier.uri	https://hdl.handle.net/20.500.12619/44419
dc.description.abstract	CONCLUSIONS: rhDNase treatment is a safe option and may be used as an effective method for the management of persistent atelectasis in newborns, which is resistant to other conventional treatment methods.
dc.language	English
dc.publisher	K FAISAL SPEC HOSP RES CENTRE
dc.subject	General & Internal Medicine
dc.title	Safety of recombinant human deoxyribonuclease as a rescue treatment for persistent atelectasis in newborns
dc.type	Article
dc.identifier.volume	32
dc.identifier.startpage	131
dc.identifier.endpage	136
dc.contributor.department	Sakarya Üniversitesi/Eğitim Fakültesi/Eğitim Bilimleri Bölümü
dc.contributor.saüauthor	İskender, Murat
dc.identifier.wos	WOS:000303036800004
dc.identifier.doi	10.5144/0256-4947.2012.131
dc.contributor.author	Atiye Fedakar
dc.contributor.author	Cavit Aydogdu
dc.contributor.author	Ali Fedakar
dc.contributor.author	Murat Ugurlucan
dc.contributor.author	Semih Bolu
dc.contributor.author	İskender, Murat